Myriad Genetics' new product aims to steer doctors to the right antidepressant for patients. But some researchers question its effectiveness, particularly in light of its high price and possible conflicts of interest. The outcome could send the shares sharply higher or lower.
Myriad Genetics' new product aims to steer doctors to the right antidepressant for patients. But some researchers question its effectiveness, particularly in light of its high price and possible conflicts of interest. The outcome could send the shares sharply higher or lower.
Share this Article
Recommended